BamSEC and AlphaSense Join Forces
Learn More

Finch Therapeutics Group Inc.

OTC: FNCH    
Share price (12/20/24): $11.00    
Market cap (12/20/24): $17.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.15
from 10-K 5 pages Retention Bonus Agreement
12/34/56
EX-10.14
from 10-K 3 pages December 7, 2022 Marc Blaustein Mblaustein@finchtherapeutics.com
12/34/56
EX-10.12
from 10-K 7 pages Consulting Agreement
12/34/56
EX-10.7
from 10-Q/A 13 pages Finch Therapeutics Group, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: March 11, 2021 Approved by the Stockholders: March 11, 2021 Ipo Date: March 18, 2021 Amended and Restated as Of: June 8, 2023
12/34/56
EX-10.6
from 10-Q/A 46 pages Finch Therapeutics Group, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: March 11, 2021 Approved by the Stockholders: March 11, 2021 Ipo Date: March 18, 2021 Amended and Restated as Of: June 8, 2023
12/34/56
EX-10.5
from 10-Q/A 23 pages Finch Therapeutics Group, Inc. 2017 Equity Incentive Plan Amended and Restated as Of: June 8, 2023
12/34/56
EX-10.1
from 10-Q/A 4 pages First Amendment to Exclusive License Agreement
12/34/56
EX-10.7
from 10-Q 13 pages Finch Therapeutics Group, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: March 11, 2021 Approved by the Stockholders: March 11, 2021 Ipo Date: March 18, 2021 Amended and Restated as Of: June 8, 2023
12/34/56
EX-10.6
from 10-Q 46 pages Finch Therapeutics Group, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: March 11, 2021 Approved by the Stockholders: March 11, 2021 Ipo Date: March 18, 2021 Amended and Restated as Of: June 8, 2023
12/34/56
EX-10.5
from 10-Q 23 pages Finch Therapeutics Group, Inc. 2017 Equity Incentive Plan Amended and Restated as Of: June 8, 2023
12/34/56
EX-10.1
from 8-K 8 pages Lease Termination Agreement
12/34/56
EX-10
from 8-K 15 pages Executive Employment Agreement
12/34/56
EX-10
from 8-K 9 pages Consulting Agreement
12/34/56
EX-10
from 10-K 5 pages Retention Bonus Agreement
12/34/56
EX-10
from 10-K 3 pages Finch Therapeutics Group, Inc. By: /S/ Mark Smith Name: Mark Smith Title: CEO Executive: /S/ Marc Blaustein Name: Marc Blaustein 2
12/34/56
EX-10.1
from 10-Q 8 pages Amendment #3 to Amended and Restated Agreement
12/34/56
EX-10.1
from 10-Q 90 pages Agreement
12/34/56
EX-10.21
from 10-K 4 pages Amendment No. 1 to Amended and Restated Executive Employment Agreement
12/34/56
EX-10.20
from 10-K 18 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.19
from 10-K 19 pages Executive Employment Agreement
12/34/56